drugset
Drugs / HS-10542
last change Mar 2026 re-read 3 minutes ago

HS-10542

Small molecule

Developed for
IgA glomerulonephritis · paroxysmal nocturnal hemoglobinuria
Investigated by
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Trials 3

today NCT07474636 · Ph 2 NCT07470762 · Ph 1/2 NCT07040046 · Ph 1
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07040046 May → Dec 2025 overdue — Jiangsu Hansoh Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07470762 Feb 2026 → May 2027 expected paroxysmal nocturnal hemoglobinuria Jiangsu Hansoh Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07474636 Mar 2026 → Dec 2027 expected IgA glomerulonephritis Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2026-03-30 Hansoh BioMedical R&D Company Results WCN 2026 | 翰森制药HS-10542（补体因子B抑制剂）健康参与者Ⅰ期临床数据发布 hansoh.cn ↗
2026-03-28 Jiangsu Hansoh Pharmaceutical Co., Ltd. Results WCN 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-10542（A COMPLEMENT FACTOR B INHIBITOR）IN HEALTHY PARTICIPANTS hspharm.com ↗
Nearly complete inhibition (>95%) was achieved at 24 hours after last dosing of MAD across doses.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as HS-10542 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07474636 ↗
2

NCT07470762 ↗

NCT07040046 ↗
Action Inhibit “inhibits factor B (FB)” NCT07470762 ↗
Modality Small molecule “HS-10542 is a novel oral small molecular weight compound” NCT07470762 ↗
Route Oral “administered orally once on Day 1” NCT07040046 ↗